Post by
Smokey1958 on Aug 10, 2021 11:14am
Financial Year End
Year end for THRM was July 31, 2021. What will Q1 2022 look like? Here are some facts and some thoughts.
1. Morningstar's Fair Value sp for THRM has already climbed almost 20%. Today it sits at $.49.
2. Barchart maintains a 56% BUY ....it was a 40% SELL exactly a month ago.
3. The sp remains relatively stable in spite of significant day trading manipulation
3. Rob Fia believes FDA EUA authorization is expected.
5. THRM already has the CE mark
6. ANVISA authorization is very likely .....should open up several testing contracts in South America
7. Ramping up for production ....the Delta Variant and disproportionate vaccination rates by country
means testing will continue to be relevant ....for at least the next two years.
8. Updates on Venowave. DME Authority appears to have staked their financial credibility almost
exclusively on Venowave.
Unfortunately it is not a matter of if but instead when the next variant surfaces, As long as vaccination rates remain low in parts of the developed world and demonstrably low in parts of the developing world the chance of another variant arising remains high. Also the varied level level of immunity amongst those vaccinated may require the very seriological test that THRM has access to sell. A win/win for THRM under this unfortunate reality.
GLTE ....holding patiently.
Comment by
peck1 on Aug 10, 2021 11:21am
Excellent summary. Thanks Smokey1958. Good things to come. Patience should be rewarded. Lets hope year end looks good. I believe it may surprise us. GLTA